#Small plus plus blocks trial
#Small plus plus blocks free

According to independent assessment, about 98% of the media sector is held by three conglomerates. Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. Media ownership in Australia is one of the most concentrated in the world ( Learn more).

#Small plus plus blocks free

We don't put up a paywall – we believe in free access to information of public interest. Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. 'If we have a better sense of who needs the added chemotherapy, we can convey that to patients and discuss the risks and benefits.'įunding: This study was funded by AstraZeneca. 'Some patients already do very well for an extended time on osimertinib alone,' says Jänne. They also will analyze the data, blood samples, and tumor biopsies they've collected to determine if there are subsets of patients who are more likely to respond to the combination therapy. The investigators will continue to observe patients to determine if overall survival is improved with the more intense therapy. 'While we don't know if that translates to an improvement in Overall Survival, osi + chemo provided significant benefit for all patients in the trial.' 'It was a significant improvement in progression-free survival,' says Jänne. Patients receiving the combination experience more adverse events associated with the added chemotherapy. The median progression-free survival for patients taking the combination was 25.5 months versus 16.7 months for those taking osimertinib alone. Patients randomized to receive the combination had four treatments of chemotherapy over the course of three months and then continued with osimertinib plus pemetrexed.

#Small plus plus blocks trial

'In this trial, we took a complementary approach and added the chemotherapy up-front to determine if it would stave off resistance,' says Jänne.Įvidence from previous studies had shown that earlier generation EGFR-TKIs plus chemotherapy had improved efficacy, suggesting that the strategy of intensifying initial therapy had merit.Īfter an initial test of the safety of the combination of osimertinib and chemotherapy, this trial randomized 557 patients with EGFR-mutated advanced NSCLC to receive either osimertinib alone or osimertinib in combination with pemetrexed plus either cisplatin or carboplatin chemotherapy. One way to treat resistance is to wait for it to occur and treat the recurrence by adding chemotherapy. However, patients can still develop resistance to the drug and relapse. Osimertinib has been shown to be more effective than previous generations of EGFR-TKIs. These patients receive standard therapy of osimertinib, a third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) that precisely targets and blocks the oncogenic mutation. The mutation fuels the growth of the cancer. Jänne presented the findings at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Singapore on Monday, September 11 at 10:05 AM SGT.Ībout 10-15% of patients in the US and 50% of patients in Asia with NSCLC harbor EGFR mutations in their tumors. 'One way to do that is to intensify the initial treatment we give.' Jänne, MD, PhD, Director of the Lowe Center for Thoracic Oncology at Dana-Farber. 'We want to develop more effective approaches for patients with non-small cell lung cancer,' says co-principal investigator Pasi A.

In a phase 3 global clinical trial called FLAURA2 led by researchers from Dana-Farber Cancer Institute and Institut Gustav Roussy in France, patients with non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation taking standard therapy plus chemotherapy had a median of nearly 9 months increase in progression free survival compared with patients taking standard therapy alone.